Letters in Drug Design & Discovery
Letters in Drug Design & Discovery
The contents of Volumes 1-22 of Letters in Drug Design & Discovery published with Bentham Science can be found here. (https://www.benthamscience.com/journal/lddd)Letters in Drug Design & Disco...
The contents of Volumes 1-22 ofLetters in Drug Design & Discovery published with Bentham Science can be found here. (https://www.benthamscience.com/journal/lddd)
Letters in Drug Design & Discovery publishes letters, full-length/mini-reviews, research articles, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of the latest Internet technology for both the submission and review of manuscripts. The journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
This journal contains four sections:
Drug Design & Discovery Analysis: This section focuses on all areas of drug identification, design, and discovery, including all fields of medicinal chemistry, as well as in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. It also encompasses neuropharmacology, component activity, natural substances and biomolecules, bio-immunosuppressive agents, and nanomaterials. Furthermore, this section examines advanced technologies such as organoid chip engineering and computer-aided drug design (including molecular modeling and structure-based drug design), as well as the application of various analytical methods, including chromatography, mass spectrometry, spectroscopy, and electrochemistry.
Biochemistry in Drug Design:This section focuses on the latest advancements in biopharmaceutical technology, encompassing the disciplines of organic chemistry, biology, and medicine. It provides an in-depth exploration of various facets of biopharmaceutical design, including antibiotics, vaccines, peptides, proteases, liposomes, polysaccharides, antibody engineering, and cell and gene engineering technologies such as high-throughput sequencing, single-cell sequencing, RNA interference, CRISPR-Cas9 gene editing, and multi-omics analysis. Furthermore, cutting-edge technologies like nanorobots and microbial fermentation, microbiolo-omics, biosimilar drug, nano-drugs and drug delivery are significant topics of discussion in this section. It also includes multi-target natural drugs, natural biomaterials, synthetic medicinal materials, tissue engineering materials (vascular tissue engineering, bone tissue engineering, skin tissue engineering, nerve tissue engineering) and seed cell research (stem cell culture and transplantation, stem cells and drugs).
Toxicology, Pharmaceutics: This section focuses on the formulation, design, and development of drugs. It encompasses toxicological assessments, pharmacodynamics, pharmacokinetics, and safety evaluations. This section involves the design and testing of drug delivery systems, including clinical trials and preclinical experiments, which are essential for ensuring optimal absorption and distribution of drugs within the body. Additionally, it pertains to drug targets and diseases in various departments, aiming to discover and optimize drug design and development.
Pharmacology & Molecular Pharmacology:This section aims to publish the latest progress of cellular and molecular pharmacology, and the pharmacological mechanism of drugs in organisms, and mainly emphasizes the mechanism of action of new drugs being developed, innovative pharmacological techniques, cell signal transduction, transduction pathway analysis, genomics, protein genomics and metabonomics in the application of drugs. Another focus will be on the ways in which knowledge of drug action at the cellular and molecular levels clarifies normal biological functions. Additionally, this section emphasizes the use of cellular and molecular tools—such as genes, proteins, and signaling pathways—to evaluate the impact of drugs on gene expression in cellular and animal models. This approach aids in identifying potential targets, assessing toxicity and sensitivity, and facilitating the design, development, and discovery of new drugs with specific mechanisms of action. This part also includes the target research of molecular biology and cell biology, which is beneficial to the research of new drugs around the target.
Fosinopril ameliorates renal injury in diabetic nephropathy by inactivating the SRC/NF-κB pathway
Xiaofeng Cheng | Zhengbo Qiao | Li Cheng | Kai Wang
Exploration of the potential molecular mechanism of magnolol in colorectal cancer treatment based on network pharmacology and molecular docking
Xianghui Liao | Tuhua Li | Li Yang | Haiwen Li | Weiru Li | Yuting Liu | Zhong Xie
The inhibitory effects of Cucurbitacin B on hypopharyngeal cancer cell malignant behaviors were investigated based on network pharmacology and molecular docking
Xinjing Liu | Xiang Liu | Tong Qiao | Jing Lei | Man Wang
1. Drug designing and synthesis of novel diphenyl 1,3,4 oxadiazoles: Multi-targeted therapeutics for the treatment of malassezia-induced dandruff
Shubham Varma | Shivam Varma | Sumit Waragade | Rachel Cordeiro | Aakash Yadav
2. Simulation, 3D-QSAR, molecular docking and pharmacophore mapping studies on indole derivatives as aromatase inhibitors
Neha Bhatia | Suresh Thareja
3. Exploration of the mechanism of quercetin against GDM based on network pharmacology and molecular docking
Xingzhe Lin | Jun Li | Yingying Cai | Yasong Hong | Jinghai Chen
Molecular Docking: Principles, Advances, and its Applications in Drug Discovery
Muhammed Tilahun Muhammed | Esin Aki-Yalcin
The New Era of Drug Discovery: The Power of Computer-aided Drug Design (CADD)
Igor José Dos Santos Nascimento | Thiago Mendonça de Aquino | Edeildo Ferreira da Silva-Júnior
Aminoalkylated phenolic chalcones: Investigation of biological effects on acetylcholinesterase and carbonic anhydrase I and II as potential lead enzyme inhibitors
Cem Yamali | Halise Inci Gul | Tahir Cakir | Yeliz Demir | Ilhami Gulcin